{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:10:58Z","timestamp":1789884658819,"version":"4.0.1"},"reference-count":44,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.4155\/fmc.12.41","type":"journal-article","created":{"date-parts":[[2012,5,9]],"date-time":"2012-05-09T16:29:47Z","timestamp":1336580987000},"page":"877-891","source":"Crossref","is-referenced-by-count":44,"title":["Farnesoid X Receptor: From Medicinal Chemistry To Clinical Applications"],"prefix":"10.1080","volume":"4","author":[{"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[{"name":"Dipartimento di Medicina Clinica e Sperimentale, Universit\u00e0 Degli Studi di Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mencarelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Clinica e Sperimentale, Universit\u00e0 Degli Studi di Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elenora","family":"Distrutti","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera di Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zampella","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica delle Sostanze Naturali, Universit\u00e0 di Napoli \u2018Federico II\u2019, via D. Montesano 49, 80131Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,5,9]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90530-8"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80348-2"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986710790112666"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.06.001"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R900010-JLR200"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2011.06.012"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2006.04.014"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00781.2006"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.06.008"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0582221"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049904b"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-1485"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.06.073"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.08006FP"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710981105"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209863200"},{"key":"e_1_3_2_3_17_1","first-page":"106","article-title":"Abstract 584: a synthetic farnesoid X receptor agonist protects against diet-induced dyslipidemia.","volume":"116","author":"Evans MJ","year":"2007","unstructured":"Evans MJ , MahaneyPE, ZhangSet al. Abstract 584: a synthetic farnesoid X receptor agonist protects against diet-induced dyslipidemia. Circulation 116, 106 (2007).","journal-title":"Circulation"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2004.07.007"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.009"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604772103"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21158"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2011.01.008"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(10)60004-9"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2009.11.001"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M400221-JLR200"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.04.026"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00062-3"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45277"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.023820"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01075.2008"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M800619-JLR200"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0030"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.248203"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2010.01.002"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.04.068"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20973"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025637"},{"key":"e_1_3_2_3_39_1","unstructured":"Henry RR MudaliarS MorrowLet al. Farnesoid-X receptor agonists: a new therapeutic class for diabetes and fatty liver disease? The first FXR therapeutic study in diabetes. Presented at: Annual Meeting of the American Diabetes Association. Chicago IL USA 6\u20139 June 2007."},{"key":"e_1_3_2_3_40_1","first-page":"389A","article-title":"A new therapy for nonalcoholic fatty liver disease and diabetes? Int-747 \u2013 the first FXR hepatic therapeutic study.","volume":"50","author":"Sanyal AJ","year":"2009","unstructured":"Sanyal AJ , MudaliarS, HenryRRet al. A new therapy for nonalcoholic fatty liver disease and diabetes? Int-747 \u2013 the first FXR hepatic therapeutic study. Hepatology 50, 389A\u2013390A (2009).","journal-title":"Hepatology"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.007054"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm200169t"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101336m"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030443"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.12.41","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:49:30Z","timestamp":1716493770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.12.41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.4155\/fmc.12.41"],"URL":"https:\/\/doi.org\/10.4155\/fmc.12.41","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}